Neurology:动脉瘤性蛛网膜下腔出血患者自我报告结果评估手段研究

2019-05-14 MedSci MedSci原创

研究认为,卒中特异性生活质量评估是目前动脉瘤性蛛网膜下腔出血患者自我报告预后的主要评估手段

患者自我报告的结果(Pros)是评估患者预后健康状况的重要手段,对建立以患者为中心的日常护理十分重要。近日研究人员开展荟萃研究,考察动脉瘤性蛛网膜下腔出血(ASAH)患者的Pros。

研究收集了截至2018年10月29日在PubMed、Cochrane中心对照试验登记和EMBASE发表的相关文献,入选研究必须评估ASAH患者特征和Pros。

9篇报道纳入本次荟萃分析,评估了ASAH患者7种不同的疾病特异性,其中5篇文献的PROS采用卒中特异性生活质量量表(SS QOL)进行预后评估,但所使用的方法证据质量较低,不符合现行荟萃研究内容有效性的标准。

研究认为,卒中特异性生活质量评估是目前动脉瘤性蛛网膜下腔出血患者自我报告预后的主要评估手段。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654475, encodeId=e57216544e553, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Sun Feb 09 01:48:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950424, encodeId=c8781950424a4, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Nov 18 21:48:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763902, encodeId=ff8e1e6390288, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Mon May 20 02:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000766, encodeId=94192000e664d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Mar 02 12:48:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337801, encodeId=d19e133e80179, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu May 16 10:48:00 CST 2019, time=2019-05-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654475, encodeId=e57216544e553, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Sun Feb 09 01:48:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950424, encodeId=c8781950424a4, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Nov 18 21:48:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763902, encodeId=ff8e1e6390288, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Mon May 20 02:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000766, encodeId=94192000e664d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Mar 02 12:48:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337801, encodeId=d19e133e80179, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu May 16 10:48:00 CST 2019, time=2019-05-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1654475, encodeId=e57216544e553, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Sun Feb 09 01:48:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950424, encodeId=c8781950424a4, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Nov 18 21:48:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763902, encodeId=ff8e1e6390288, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Mon May 20 02:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000766, encodeId=94192000e664d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Mar 02 12:48:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337801, encodeId=d19e133e80179, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu May 16 10:48:00 CST 2019, time=2019-05-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654475, encodeId=e57216544e553, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Sun Feb 09 01:48:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950424, encodeId=c8781950424a4, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Nov 18 21:48:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763902, encodeId=ff8e1e6390288, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Mon May 20 02:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000766, encodeId=94192000e664d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Mar 02 12:48:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337801, encodeId=d19e133e80179, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu May 16 10:48:00 CST 2019, time=2019-05-16, status=1, ipAttribution=)]
    2020-03-02 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1654475, encodeId=e57216544e553, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Sun Feb 09 01:48:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950424, encodeId=c8781950424a4, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Nov 18 21:48:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763902, encodeId=ff8e1e6390288, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Mon May 20 02:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000766, encodeId=94192000e664d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Mar 02 12:48:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337801, encodeId=d19e133e80179, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu May 16 10:48:00 CST 2019, time=2019-05-16, status=1, ipAttribution=)]

相关资讯

Stroke:高血压对动脉瘤性蛛网膜下腔出血后迟发性脑缺血的影响

诱发高血压对于治疗动脉瘤性蛛网膜下腔出血后迟发性脑缺血的假设的作用只是基于没有对照的病例基础上的。研究人员在一项随机临床试验中评估了诱发高血压对动脉瘤性蛛网膜下腔出血患者迟发性脑缺血的脑血流(CBF)的影响。动脉瘤性蛛网膜下腔出血患者在迟发性脑缺血发作时被随机分为诱发或无诱发高血压(对照组)。 CBF评估,双盲治疗分配,迟发性脑缺血发作和研究治疗后24至36小时CT灌注在标准化的预先限定的区域进行

Neurology:脑出血后谷氨酰胺水平降低导致感染风险增加

研究认为动脉瘤性蛛网膜下腔出血后谷氨酰胺水平降低导致医院获得性感染风险增加

Am J Emerg Med:入院乳酸水平可能预测动脉瘤性蛛网膜下腔出血死亡率

背景:动脉瘤性蛛网膜下腔出血(SAH)是出血性脑卒中的最具破坏性的形式。主要根据初步临床表现预测死亡的发生。初始血清乳酸水平已被证明可以预测死亡和疾病的严重程度。初始血清乳酸可能是一个客观的预测因子或死亡率。方法:回顾性分析一个大型学术中心超过42个月的,动脉瘤性蛛网膜下腔出血的患者。。收集的数据包括人口统计数据,临床数据,血清和临床预后数据。在基线时收集流行病学资料,并对住院病人进行随访。研究者

Stroke:动脉瘤性蛛网膜下腔出血患者额叶激活增强

该研究已经证实在执行任务过程中为取得好的表现,前扣带回和前基底区域激活更加明显,前扣带回激活程度与认知(蒙特利尔认知评价)评分呈负相关。

Stroke:动脉瘤性蛛网膜下腔出血患者使用大麻脑血管风险增加

目前对于动脉瘤性蛛网膜下腔出血(aSAH)患者使用大麻事件,以及其对于发病率,死亡率和结果的影响都是未知的。该研究的目的是评估aSAH患者使用大麻和结果之间的关系。2010年和2015年之间,来自美国德克萨斯大学的研究人员对aSAH连续收治病人的记录进行了审查。尿液药物筛选为阴性的aSAH患者的临床特征及结果与大麻阳性(CB+)的结果进行了比较。回归分析用于评估关联性。该研究组共包括108例患者;

Stroke:动脉瘤性蛛网膜下腔出血后院内死亡的预测因素!

由此可见,几个因素(其中包含可改变的因素)似乎与动脉瘤性蛛网膜下腔出血后院内死亡有关。 该研究的数据表明旨在降低再出血风险的策略在积极治疗的患者中是最有运用前景的。